C. Furberg

Economics and Econometrics · 2000–2011

A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom C. Furberg trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Thomas Lumley

Who trusts C. Furberg overall

  1. V. Basevi
  2. D. Nathan

Papers from C. Furberg's perspective

Ordered by how strongly the researchers C. Furberg trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. (Circulation)
  2. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention… (Circulation)
  3. Network meta‐analysis for indirect treatment comparisons (Statistics in Medicine)
  4. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. (Journal of the American Medical Association (JAMA))
  5. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
  6. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses (British medical journal)
  7. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. (Journal of the American Medical Association (JAMA))
  8. Effects of torcetrapib in patients at high risk for coronary events. (New England Journal of Medicine)
  9. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. (Journal of the American Medical Association (JAMA))
  10. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (Circulation)

Their papers